The biotechnology firm said Adams’ role will be to manage and oversee all matters relating to its pre-clinical and clinical drug development programs and associated intellectual property.
READ: Tiziana Life Sciences: HC Wainwright analyst flags the "intriguing evidence of therapeutic utility" for nasally administered Covid antibody treatment
Adams holds a PhD in Biochemistry from the University of California, Riverside, and previously served as chief executive and executive chairman of cancer therapy firm Cardiff Oncology (NASDAQ:CRDF). He also currently serves as a director at Hepion Pharmaceuticals Inc (NASDAQ:HEPA), which focuses on the development of treatments for liver disease.
"I am excited to join the team at Tiziana to focus on developing foralumab and milciclib. These new targeted therapies promise to deliver relief to patients suffering from cancer, inflammatory and infectious disease. My experience in precision medicine utilizing targeted therapies with precision diagnostics should accelerate the delivery of these important therapeutics", Adams said in a statement.
"We are delighted to welcome Dr Adams to the board and consider that his proven track record in the field of cancer could add significant value to the development of the company's Milciclib and Foralumab oncology programs", added Tiziana chairman Gabriele Cerrone.